☆ 4.6 Letter

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?

AUTOIMMUNITY REVIEWS (2020)

期刊

AUTOIMMUNITY REVIEWS

卷 19, 期 7, 页码 -

出版社

ELSEVIER

DOI: 10.1016/j.autrev.2020.102564

关键词

-

类别

Immunology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy

Anna Lebedeva, Ivan Molodtsov, Alexandra Anisimova, Anastasia Berestovskaya, Oleg Dukhin, Antonina Elizarova, Wendy Fitzgerald, Darya Fomina, Kseniya Glebova, Oxana Ivanova, Anna Kalinskaya, Anastasia Lebedeva, Maryana Lysenko, Elena Maryukhnich, Elena Misyurina, Denis Protsenko, Alexander Rosin, Olga Sapozhnikova, Denis Sokorev, Alexander Shpektor, Daria Vorobyeva, Elena Vasilieva, Leonid Margolis

Summary: COVID-19 patients with cytokine storm syndrome (CSS) and those without formed distinct clusters based on their cytokine concentrations. However, the administration of tocilizumab therapy did not fully correspond to these CSS clusters. IL-1RA was found to be prognostically significant in both groups and may be useful in defining the onset of a cytokine storm and indicating anti-cytokine therapy in COVID-19.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Immunology

Repurposed Tocilizumab in Patients with Severe COVID-19

Jianbo Tian, Ming Zhang, Meng Jin, Fengqin Zhang, Qian Chu, Xiaoyang Wang, Can Chen, Huihui Yue, Li Zhang, Ronghui Du, Dong Zhao, Zhaofu Zeng, Yang Zhao, Kui Liu, Mengmei Wang, Ke Hu, Xiaoping Miao, Huilan Zhang

Summary: This study found that tocilizumab treatment in COVID-19 patients can lower the risk of in-hospital death and acute respiratory distress syndrome. Patients had heightened inflammation and dysregulated immune cells before treatment, but these indicators improved after tocilizumab administration.

JOURNAL OF IMMUNOLOGY (2021)

添加到收藏夹

Article Virology

Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome

Oleksandr Oliynyk, Wojciech Barg, Anna Slifirczyk, Yanina Oliynyk, Vitaliy Gurianov, Marta Rorat

Summary: The study identified three subtypes of cytokine storm in COVID-19 patients: CRS, MAS, and sepsis. Tocilizumab therapy was associated with reduced mortality in MAS patients but increased mortality in CRS patients.

VIRUSES-BASEL (2021)

添加到收藏夹

Article Health Care Sciences & Services

Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection

Al Shaimaa Ibrahim Rabie, Hager Salah, Amira S. A. Said, Ahmed Hassan Shaaban, Lamya Mohamed Abdou, Doaa Mahmoud Khalil, Zelal Kharaba, Hala Afifi, Mahmoud R. Sofy, Eman M. I. Youssef, Eman S. M. Bayoumy, Raghda R. S. Hussein

Summary: There are currently no therapeutic medications for severe COVID-19 infection. Tocilizumab, an immunomodulatory treatment, was hypothesized to reduce inflammation in the respiratory system and prevent the need for ventilators. However, a randomized controlled trial found that tocilizumab was ineffective in preventing intubation or death in hospitalized patients with severe illness and COVID-19.

HEALTHCARE (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: Less is more

Niels W. Boone, Dirk Jan A. R. Moes, Sofia Ramiro, Remy L. M. Mostard, Cesar Magro-Checa, Christel M. P. van Dongen, Michiel Gronenschild, Eric van Haren, Jacqueline Buijs, Annick de Vries, Ralph Peeters, Robert B. M. Landewe, Dennis R. Wong

Summary: This study evaluated the pharmacokinetics of a single dose of interleukin-6 (IL-6) antibody tocilizumab (TCZ) in methylprednisolone (MP)-treated COVID-19 patients with cytokine storm syndrome (CSS). The results showed that a single dose of 8 mg/kg of TCZ (maximum dose of 800 mg) was sufficient to cover 16 days of IL-6-mediated hyperinflammation in COVID-19-induced CSS.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

添加到收藏夹

Review Infectious Diseases

Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis

Qiu Wei, Hua Lin, Rong-Guo Wei, Nian Chen, Fan He, Dong-Hua Zou, Jin-Ru Wei

Summary: The study suggests that tocilizumab treatment is associated with a lower risk of mortality and reduced need for mechanical ventilation among COVID-19 patients. Tocilizumab may have a substantial effectiveness in reducing mortality, especially in critical cases, providing up-to-date evidence of its potential therapeutic role in COVID-19 management.

INFECTIOUS DISEASES OF POVERTY (2021)

添加到收藏夹

Article Infectious Diseases

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study

Edmund Huang, Sharon Isonaka, Haoshu Yang, Erin Salce, Elisa Rosales, Stanley C. Jordan

Summary: This retrospective study compared outcomes among critically ill COVID-19 patients treated with tocilizumab and those who were not. The results showed that tocilizumab treatment was associated with lower mortality rates, especially in patients requiring mechanical ventilation.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in COVID-19 interstitial pneumonia

G. Pomponio, A. Ferrarini, M. Bonifazi, M. Moretti, A. Salvi, A. Giacometti, M. Tavio, G. Titolo, L. Morbidoni, G. Frausini, M. Onesta, D. Amico, M. L. B. Rocchi, S. Menzo, L. Zuccatosta, F. Mei, V. Menditto, S. Svegliati, A. Donati, M. M. D'Errico, M. Pavani, A. Gabrielli

Summary: This study utilized a structured design to identify predictive factors for response to tocilizumab in COVID-19 patients and aims to improve the design of future randomized trials. Lower levels of IL-6 and higher baseline values of PaO2/FiO(2) were found to predict a favorable response to tocilizumab.

JOURNAL OF INTERNAL MEDICINE (2021)

添加到收藏夹

Article Immunology

Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis

Mathilde Roumier, Romain Paule, Alexandre Vallee, Julien Rohmer, Marie Ballester, Anne-Laure Brun, Charles Cerf, Marie-Laure Chabi, Thierry Chinet, Marie-Alice Colombier, Eric Farfour, Erwan Fourn, Guillaume Geri, David Khau, Ibrahim Marroun, Matthieu Ponsoye, Antoine Roux, Helene Salvator, Yoland Schoindre, Anne-Gaelle Si Larbi, Colas Tcherakian, Marc Vasse, Anne Verrat, Benjamin Zuber, Louis-Jean Couderc, Jean-Emmanuel Kahn, Matthieu Groh, Felix Ackermann

Summary: Treatment with tocilizumab in patients with severe COVID-19 pneumonia showed reduced need for overall ventilatory support, an increased rate of oxygen withdrawal, and higher discharge rate at D28. However, there was no significant improvement in overall survival. Higher rates of neutropenia were observed in the tocilizumab group, while rates of infections, including ventilator-acquired pneumonia, were higher in the control group. These findings could guide future trials aimed at managing COVID-19-induced inflammation, particularly before ICU admission.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Review Immunology

Neutrophil Extracellular Traps, Sepsis and COVID-19-A Tripod Stand

Esmeiry Ventura-Santana, Joshua R. Ninan, Caitlin M. Snyder, Emeka B. Okeke

Summary: Severe COVID-19 affects about 20% of patients, leading to clinical manifestations such as ARDS and sepsis. The formation of neutrophil extracellular traps (NETs) is associated with severe cases. Understanding the immunopathology of COVID-19 is crucial for the development of effective therapies.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Tocilizumab and COVID-19: Timing of Administration and Efficacy

Emna Abidi, Wasim S. El Nekidy, Eman Alefishat, Nadeem Rahman, Georg A. Petroianu, Rania El-Lababidi, Jihad Mallat

Summary: Elevated IL-6 levels play a key role in COVID-19 immune impairment, with tocilizumab being investigated as a potential treatment by targeting IL-6 receptor antagonism. While early observational studies show benefits, subsequent randomized trials have produced conflicting results regarding tocilizumab's efficacy as a standard therapy for COVID-19 pneumonia.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Article Rheumatology

Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls

Ali Mert, Haluk Vahaboglu, Ferhat Arslan, Ayse Batirel, Kemal Tolga Saracoglu, Aliye Bastug, Atahan Cagatay, Ilim Irmak, Gulcin Telli Dizman, Ihsan Ertenli, Lutfiye Nilsun Altunal, Buket Erturk Sengel, Mehmet Bayram, Ahmet Omma, Shirkhan Amikishiyev, Adalet Aypak, Cemal Bes, Sibel Bolukcu, Sacit Icten, Arzu Topeli, Murat Bektas, Birsen Yigit Arslan, Sinan Ozturk, Senol Comoglu, Selda Aydin, Orhan Kucuksahin, Ozan Cemal Icacan, Burak Ince, Sarvan Aghamuradov, Melek Yalcin Mutlu, Funda Simsek, Salih Emre, Cemal Ustun, Pinar Ergen, Ozlem Aydin, Meliha Meric Koc, Omur Gokmen Sevindik, Zekaver Odabasi, Volkan Korten, Hurrem Bodur, Rahmet Guner, Serhat Unal, Mehmet Kocak, Ahmet Gul

Summary: While tocilizumab users showed more frequent intubation or death, PS-matched analyses based on gender, ferritin, and procalcitonin levels revealed that tocilizumab may be effective in a subset of patients.

RHEUMATOLOGY INTERNATIONAL (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

COVID-19 and IL-6: Why vitamin D (probably) helps but tocilizumab might not

Morry Silberstein

Summary: Vitamin D may be more effective than IL-6 antagonists like tocilizumab in treating COVID-19, as it modulates IL-6 immune responses and potentially reduces pro-inflammatory effects. Current studies indicate a positive therapeutic effect of Vitamin D in COVID-19 patients, providing a strong rationale for its use.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19

Allen Widysanto, Andree Kurniawan, Nata Pratama Hardjo Lugito, Mira Yuniarti, Catherine Gunawan, Angela, Jessica Wiryanto, Levinna, Tasya Meidy Pradhana

Summary: COVID-19 is a global public health emergency, with various clinical manifestations and severe outcomes associated with comorbidities. Severe cases of COVID-19 are linked to increased levels of IL-6 and cytokine storms, with tocilizumab showing promise as a potential therapy. Limited studies on its efficacy warrant further research.

CYTOKINE (2021)

添加到收藏夹

Article Immunology

Tocilizumab in critically ill COVID-19 patients: An observational study

Muhammad Z. Mushtaq, Saad B. Z. Mahmood, Aysha Almas, Syed Ather Wasti, Syed Ahsan Ali

Summary: This study examined the response of tocilizumab in COVID-19 patients by analyzing clinical parameters and inflammatory markers. The results showed that tocilizumab can decrease the need for mechanical ventilation and improve inflammatory markers and neutrophil to lymphocyte ratio. However, it is associated with adverse events including bacterial and fungal infections.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Impact of HCV eradication with direct-acting antiviral agents on serum gamma globulin levels in HCV and HCV/HIV coinfected patients

Laura Milazzo, Lorena van den Bogaart, Salvatore Sollima, Letizia Oreni, Alessia Lai, Valentina Morena, Cecilia Bonazzetti, Lisa Ridolfo Anna, Spinello Antinori

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2020)

添加到收藏夹

Review Medicine, General & Internal

Chagas disease in Italy: the study's contribution of Italian researchers

Spinello Antinori, Anna L. Ridolfo, Andrea Giacomelli, Cecilia Bonazzetti, Mario Corbellino, Massimo Galli

PANMINERVA MEDICA (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study

Andrea Giacomelli, Anna Lisa Ridolfo, Laura Milazzo, Letizia Oreni, Dario Bernacchia, Matteo Siano, Cecilia Bonazzetti, Alice Covizzi, Marco Schiuma, Matteo Passerini, Marco Piscaglia, Massimo Coen, Guido Gubertini, Giuliano Rizzardini, Chiara Cogliati, Anna Maria Brambilla, Riccardo Colombo, Antonio Castelli, Roberto Rech, Agostino Riva, Alessandro Torre, Luca Meroni, Stefano Rusconi, Spinello Antinori, Massimo Galli

PHARMACOLOGICAL RESEARCH (2020)

添加到收藏夹

Editorial Material Public, Environmental & Occupational Health

Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: A diagnostic challenge

Spinello Antinori, Roberto Rech, Laura Galimberti, Antonio Castelli, Elena Angeli, Tommaso Fossali, Davide Bernasconi, Alice Covizzi, Cecilia Bonazzetti, Alessandro Torre, Luca Carsana, Cristina Tonello, Pietro Zerbi, Manuela Nebuloni

TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status

Spinello Antinori, Maria Vittoria Cossu, Anna Lisa Ridolfo, Roberto Rech, Cecilia Bonazzetti, Gabriele Pagani, Guido Gubertini, Massimo Coen, Carlo Magni, Antonio Castelli, Beatrice Borghi, Riccardo Colombo, Riccardo Giorgi, Elena Angeli, Davide Mileto, Laura Milazzo, Stefania Vimercati, Martina Pellicciotta, Mario Corbellino, Alessandro Torre, Stefano Rusconi, Letizia Oreni, Maria Rita Gismondo, Andrea Giacomelli, Luca Meroni, Giuliano Rizzardini, Massimo Galli

PHARMACOLOGICAL RESEARCH (2020)

添加到收藏夹

Letter Public, Environmental & Occupational Health

SARS-COV-2 infection: Across the border into the family

Spinello Antinori, Alessandro Torre, Carolina Antinori, Cecilia Bonazzetti, Salvatore Sollima, Anna Lisa Ridolfo, Massimo Galli

TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)

添加到收藏夹

Review Public, Environmental & Occupational Health

Trypanosoma cruzi infection in Latin American pregnant women living outside endemic countries and frequency of congenital transmission: a systematic review and meta-analysis

Valeria Colombo, Andrea Giacomelli, Giovanni Casazza, Laura Galimberti, Cecilia Bonazzetti, Federico Sabaini, Anna Lisa Ridolfo, Spinello Antinori

Summary: The study found that the prevalence of Trypanosoma cruzi infection among Latin American pregnant women living outside endemic countries is generally high, especially in Bolivian women. The vertical transmission rate of T. cruzi infection is similar to the rate reported in South and Central American countries.

JOURNAL OF TRAVEL MEDICINE (2021)

添加到收藏夹

Article Geriatrics & Gerontology

Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients

Dario Cattaneo, Luca Pasina, Aldo Pietro Maggioni, Letizia Oreni, Federico Conti, Laura Pezzati, Giacomo Casalini, Cecilia Bonazzetti, Valentina Morena, Annalisa Ridolfo, Spinello Antinori, Cristina Gervasoni

Summary: This study assessed the risk of DDIs and PIMs in COVID-19 patients at hospital discharge. It found a significant increase in the prescription of proton pump inhibitors and heparins at discharge, resulting in a higher risk of potentially severe DDIs.

DRUGS & AGING (2021)

添加到收藏夹

Letter Infectious Diseases

Comment on: Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU

Cecilia Bonazzetti, Laura Milazzo, Andrea Giacomelli, Letizia Oreni, Riccardo Colombo, Anna Lisa Ridolfo, Spinello Antinori

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

添加到收藏夹

Article Virology

Impact of gender on patients hospitalized for SARS-COV-2 infection: A prospective observational study

Andrea Giacomelli, Teresa De Falco, Letizia Oreni, Alice Pedroli, Anna Lisa Ridolfo, Elisa Calabro, Giorgia Carrozzo, Cecilia Bonazzetti, Spinello Antinori, Antonio Brucato

Summary: Analysis of COVID-19 patient cases showed that male patients are more likely to present critically ill upon hospital admission, while age, critical disease at hospital admission, and obesity are associated with higher odds of death.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Risks of potential drug-drug interactions in COVID-19 patients treated with corticosteroids: a single-center experience

D. Cattaneo, L. Pasina, F. Conti, A. Giacomelli, L. Oreni, L. Pezzati, C. Bonazzetti, M. Piscaglia, G. Carrozzo, S. Antinori, C. Gervasoni

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2021)

添加到收藏夹

Article Microbiology

Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients

Marco Masetti, Maria Francesca Scuppa, Alessio Aloisio, Laura Giovannini, Laura Borgese, Stefania Manno, Beatrice Tazza, Renato Pascale, Cecilia Bonazzetti, Natascia Caroccia, Mario Sabatino, Giosafat Spitaleri, Pierluigi Viale, Maddalena Giannella, Luciano Potena

Summary: Heart transplantation patients have a higher risk of COVID-19 and the efficacy of vaccines is lower, especially after the third or fourth dose. Mycophenolate therapy and recent transplantation are associated with an increased risk of infection and reduced efficacy of the fourth dose.

MICROORGANISMS (2023)

添加到收藏夹

Article Critical Care Medicine

Unexpectedly High Frequency of Enterococcal Bloodstream Infections in Coronavirus Disease 2019 Patients Admitted to an Italian ICU: An Observational Study

Cecilia Bonazzetti, Valentina Morena, Andrea Giacomelli, Letizia Oreni, Giacomo Casalini, Laura Rina Galimberti, Matteo Bolis, Matteo Rimoldi, Elisabetta Ballone, Riccardo Colombo, Anna Lisa Ridolfo, Spinello Antinori

Summary: This study assessed the frequency of ICU-acquired bloodstream infections in coronavirus disease 2019 patients, finding a high infection rate mainly caused by gram-positive bacteria, with Enterococcus being the most common. Patients with bloodstream infections had higher organ failure scores upon ICU admission, longer ICU stays, and more frequent need for invasive mechanical ventilation.

CRITICAL CARE MEDICINE (2021)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.